Cargando…

The Profile of Autoimmunity in Type 1 Diabetes Patients

BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other aut...

Descripción completa

Detalles Bibliográficos
Autores principales: Derrou, Sara, El Guendouz, Fayçal, Benabdelfedil, Yousra, Chakri, Imad, Ouleghzal, Hassan, Safi, Somaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102891/
https://www.ncbi.nlm.nih.gov/pubmed/33727507
http://dx.doi.org/10.4103/aam.aam_8_20
_version_ 1783689199135752192
author Derrou, Sara
El Guendouz, Fayçal
Benabdelfedil, Yousra
Chakri, Imad
Ouleghzal, Hassan
Safi, Somaya
author_facet Derrou, Sara
El Guendouz, Fayçal
Benabdelfedil, Yousra
Chakri, Imad
Ouleghzal, Hassan
Safi, Somaya
author_sort Derrou, Sara
collection PubMed
description BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other autoimmune reactions, which may involve other organs, resulting in organ specific autoimmune disease. The most frequently encountered are autoimmune thyroid disease, followed by celiac and gastric disease and other rare autoimmune diseases. OBJECTIVES: The purpose of this study is to investigate the prevalence of autoimmune markers in patients with T1DM. METHODS: The study was conducted at the Department of Endocrinology of the Military Hospital Moulay Ismail in Meknes Morocco, from January 2016 to December 2018. All Type 1 diabetes patients consulting during the study period were included in the study. Their clinical and biochemical data were collected at their first presentation, made up of anti-pancreatic antibodies (glutamic acid decarboxylase [GAD] antibody, tyrosine phosphatase antibody, and islet cell antibody) and other organ-specific antibodies: the thyroid (antithyroid peroxidase antibody, antithyroglobulin antibody, and antithyroid-stimulating hormone receptor antibody), the intestine (IgA antitissue transglutaminase antibody), the adrenal gland (anti-21 hydroxylase antibody), and the stomach (antigastric parietal cell antibody and anti-intrinsic factor antibody). RESULTS: Fifty-four patients were included, with an average age of 26 years. GAD, tyrosine phosphatase, and islet cell antibodies were detected in 74%, 22%, and 3.7%, respectively, of the 54 patients examined. The prevalence of extrapancreatic autoimmunity was 45% with a large preponderance among different immunities of those from thyroid and celiac diseases (CDs). CONCLUSION: Our results confirm that patients with Type 1 diabetes should be investigated for the presence of autoimmune diseases mainly from thyroid and CDs.
format Online
Article
Text
id pubmed-8102891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81028912021-06-02 The Profile of Autoimmunity in Type 1 Diabetes Patients Derrou, Sara El Guendouz, Fayçal Benabdelfedil, Yousra Chakri, Imad Ouleghzal, Hassan Safi, Somaya Ann Afr Med Original Article BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other autoimmune reactions, which may involve other organs, resulting in organ specific autoimmune disease. The most frequently encountered are autoimmune thyroid disease, followed by celiac and gastric disease and other rare autoimmune diseases. OBJECTIVES: The purpose of this study is to investigate the prevalence of autoimmune markers in patients with T1DM. METHODS: The study was conducted at the Department of Endocrinology of the Military Hospital Moulay Ismail in Meknes Morocco, from January 2016 to December 2018. All Type 1 diabetes patients consulting during the study period were included in the study. Their clinical and biochemical data were collected at their first presentation, made up of anti-pancreatic antibodies (glutamic acid decarboxylase [GAD] antibody, tyrosine phosphatase antibody, and islet cell antibody) and other organ-specific antibodies: the thyroid (antithyroid peroxidase antibody, antithyroglobulin antibody, and antithyroid-stimulating hormone receptor antibody), the intestine (IgA antitissue transglutaminase antibody), the adrenal gland (anti-21 hydroxylase antibody), and the stomach (antigastric parietal cell antibody and anti-intrinsic factor antibody). RESULTS: Fifty-four patients were included, with an average age of 26 years. GAD, tyrosine phosphatase, and islet cell antibodies were detected in 74%, 22%, and 3.7%, respectively, of the 54 patients examined. The prevalence of extrapancreatic autoimmunity was 45% with a large preponderance among different immunities of those from thyroid and celiac diseases (CDs). CONCLUSION: Our results confirm that patients with Type 1 diabetes should be investigated for the presence of autoimmune diseases mainly from thyroid and CDs. Wolters Kluwer - Medknow 2021 2021-03-13 /pmc/articles/PMC8102891/ /pubmed/33727507 http://dx.doi.org/10.4103/aam.aam_8_20 Text en Copyright: © 2021 Annals of African Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Derrou, Sara
El Guendouz, Fayçal
Benabdelfedil, Yousra
Chakri, Imad
Ouleghzal, Hassan
Safi, Somaya
The Profile of Autoimmunity in Type 1 Diabetes Patients
title The Profile of Autoimmunity in Type 1 Diabetes Patients
title_full The Profile of Autoimmunity in Type 1 Diabetes Patients
title_fullStr The Profile of Autoimmunity in Type 1 Diabetes Patients
title_full_unstemmed The Profile of Autoimmunity in Type 1 Diabetes Patients
title_short The Profile of Autoimmunity in Type 1 Diabetes Patients
title_sort profile of autoimmunity in type 1 diabetes patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102891/
https://www.ncbi.nlm.nih.gov/pubmed/33727507
http://dx.doi.org/10.4103/aam.aam_8_20
work_keys_str_mv AT derrousara theprofileofautoimmunityintype1diabetespatients
AT elguendouzfaycal theprofileofautoimmunityintype1diabetespatients
AT benabdelfedilyousra theprofileofautoimmunityintype1diabetespatients
AT chakriimad theprofileofautoimmunityintype1diabetespatients
AT ouleghzalhassan theprofileofautoimmunityintype1diabetespatients
AT safisomaya theprofileofautoimmunityintype1diabetespatients
AT derrousara profileofautoimmunityintype1diabetespatients
AT elguendouzfaycal profileofautoimmunityintype1diabetespatients
AT benabdelfedilyousra profileofautoimmunityintype1diabetespatients
AT chakriimad profileofautoimmunityintype1diabetespatients
AT ouleghzalhassan profileofautoimmunityintype1diabetespatients
AT safisomaya profileofautoimmunityintype1diabetespatients